Vor Biopharma (NASDAQ: VOR) net income
Vor Biopharma reported a net loss of $696.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $116.9m. Earnings per share were −$70.50.
Vor Biopharma's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$696.0m | — | — | −$70.50 |
| 2024 | −$116.9m | — | — | −$1.70 |
| 2023 | −$117.9m | — | — | −$1.75 |
| 2022 | −$92.1m | — | — | −$2.33 |
| 2021 | −$68.9m | — | — | −$2.10 |
| 2020 | −$43.3m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Vor Biopharma net income compared with its sector
By net income for its latest fiscal year, Vor Biopharma ranks 483rd of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 481st | Dentsply Sirona | −$598.0m | −16.3% |
| 482nd | Recursion Pharmaceuticals | −$644.8m | −863.4% |
| 483rd | Vor Biopharma | −$696.0m | — |
| 484th | Sarepta Therapeutics | −$713.4m | −32.5% |
| 485th | BridgeBio Pharma | −$732.9m | −146.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Vor Biopharma
- How much did Vor Biopharma earn in fiscal 2025?
- Vor Biopharma reported a net loss of $696.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $116.9m.
- What are the earnings per share of Vor Biopharma?
- They were −$70.50 in fiscal 2025, compared with −$1.70 in fiscal 2024.
- Where does Vor Biopharma rank in its sector by net income?
- It ranks 483rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Vor Biopharma come from?
- From the annual report (Form 10-K) that Vor Biopharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Vor Biopharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Vor Biopharma: the Vor Biopharma page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.